Variable | Average ± SD | Range |
---|---|---|
Age (years) | 71 ± 8 | 43-89 |
Gender (% male) | 72 | |
BMI (kg/m2) | 30 ± 5 | |
Smoking (pack-years) | 22 ± 20 | 0 - 113 |
MDD diagnosis | ||
Clinical-radiographic-pathologic (%) | 37 (30) | |
Clinical-radiographic (%) | 86 (70) | |
FVC (% pred) | 82 ± 21 | 38 - 132 |
TLC (% pred) | 73 ± 16 | 40 - 118 |
DLCO (% pred) | 50 ± 18 | 17 - 97 |
Antifibrotic therapy (%) | 84 (68) | |
Pirfenidone (%) | 39 (32) | |
Nintedanib (%) | 23 (18) | |
Switched therapy (%) | 22 (18) | |
Duration of antifibrotic therapy if any (months) | 24 ± 23 | 1-82 |
Outcomes | ||
Alive without LTx (%) | 69 (56) | |
LTx (%) | 11 (9) | |
Dead (%) | 43 (35) | |
HRCT scan pattern | ||
Definite UIP (%) | 49 (40) | |
Probable UIP (%) | 43 (35) | |
Indeterminate for UIP (%) | 5 (4) | |
Alternative diagnosis (%) | 26 (21) | |
Concomitant emphysema (%) | 46 (37) |